A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells
- PMID: 11431370
A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells
Abstract
A major obstacle to successful treatment of colorectal cancer is chemotherapy resistance. Enhanced expression of variant CD44 isoforms has been associated with aggressive tumor behavior, prompting the question of whether signaling from this receptor might modulate drug sensitivity. Activation of variant CD44 in colon carcinoma cell lines triggered resistance to the drug 1,3-bis(2-chloroethyl)-1-nitrosurea. Resistance was induced by monoclonal antibodies directed against epitopes independent of the hyaluronate-binding region but was not triggered by identical treatment of a carcinoma line expressing the standard CD44 isoform. We observed that variant CD44 produced activation of the src-family tyrosine kinase lyn. Moreover, overexpression of dominant-active lyn recapitulated chemoresistance via a pathway shown to involve activation of phosphoinositide 3-kinase and Akt. These results establish a novel role for CD44 in determining survival of colon carcinoma cells through lyn kinase and Akt. The ability to suppress apoptosis might play a critical role in the onset and development of colorectal malignancies.
Similar articles
-
CD44 regulates cell migration in human colon cancer cells via Lyn kinase and AKT phosphorylation.Exp Mol Pathol. 2007 Oct;83(2):207-15. doi: 10.1016/j.yexmp.2007.04.008. Epub 2007 May 13. Exp Mol Pathol. 2007. PMID: 17599831
-
The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner.Cancer Res. 2002 Aug 1;62(15):4307-15. Cancer Res. 2002. PMID: 12154034
-
Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.Clin Cancer Res. 2004 Dec 1;10(23):8059-67. doi: 10.1158/1078-0432.CCR-04-0035. Clin Cancer Res. 2004. PMID: 15585641
-
A novel signaling pathway associated with Lyn, PI 3-kinase and Akt supports the proliferation of myeloma cells.Biochem Biophys Res Commun. 2010 Feb 12;392(3):415-20. doi: 10.1016/j.bbrc.2010.01.038. Epub 2010 Jan 15. Biochem Biophys Res Commun. 2010. PMID: 20079716
-
The role of Src in colon cancer and its therapeutic implications.Clin Colorectal Cancer. 2014 Mar;13(1):5-13. doi: 10.1016/j.clcc.2013.10.003. Epub 2013 Nov 13. Clin Colorectal Cancer. 2014. PMID: 24361441 Review.
Cited by
-
TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability.Cell Death Dis. 2021 May 8;12(5):463. doi: 10.1038/s41419-021-03734-4. Cell Death Dis. 2021. PMID: 33966039 Free PMC article.
-
Functions of the Lyn tyrosine kinase in health and disease.Cell Commun Signal. 2012 Jul 17;10(1):21. doi: 10.1186/1478-811X-10-21. Cell Commun Signal. 2012. PMID: 22805580 Free PMC article.
-
Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer.Front Immunol. 2015 May 6;6:201. doi: 10.3389/fimmu.2015.00201. eCollection 2015. Front Immunol. 2015. PMID: 25999946 Free PMC article. Review.
-
CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway.PLoS One. 2011;6(9):e24217. doi: 10.1371/journal.pone.0024217. Epub 2011 Sep 6. PLoS One. 2011. PMID: 21915300 Free PMC article.
-
New Insights into the Crossroads between EMT and Stemness in the Context of Cancer.J Clin Med. 2016 Mar 12;5(3):37. doi: 10.3390/jcm5030037. J Clin Med. 2016. PMID: 26985909 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous